Biogen Inc (NASDAQ:BIIB)

284.81
Delayed Data
As of Feb 22
 -1.29 / -0.45%
Today’s Change
244.28
Today|||52-Week Range
370.57
-10.60%
Year-to-Date
What's in the Cards for Ionis (IONS) This Earnings Season?
Feb 22 / Zacks.com - Paid Partner Content
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
Feb 15 / Zacks.com - Paid Partner Content
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
Feb 21 / Zacks.com - Paid Partner Content
Merck (MRK) Halts Another Late Stage Study on Alzheimer's
Feb 14 / Zacks.com - Paid Partner Content
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
Feb 16 / Zacks.com - Paid Partner Content
3 ETFs to Watch on Biotech Earnings
Feb 10 / Zacks.com - Paid Partner Content
FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments
Feb 16 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
Feb 09 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close286.10
Today’s open287.70
Day’s range283.97 - 291.91
Volume2,484,736
Average volume (3 months)1,396,265
Market cap$60.5B
Data as of 4:00pm ET, 02/22/2018

Growth & Valuation

Earnings growth (last year)-29.56%
Earnings growth (this year)+13.87%
Earnings growth (next 5 years)+4.47%
Revenue growth (last year)+7.81%
P/E ratio23.9
Price/Sales6.17
Price/Book4.80

Competitors

 Today’s
change
Today’s
% change
ILMNIllumina Inc-1.17-0.51%
GILDGilead Sciences-1.29-1.60%
----
BIVVBioverativ Inc+0.39+0.38%
Data as of 4:15pm ET, 02/22/2018

Financials

Next reporting dateApril 26, 2018
EPS forecast (this quarter)$5.47
Annual revenue (last year)$11.0B
Annual profit (last year)$2.5B
Net profit margin23.10%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Senior Vice President-
US Therapeutic Operations
Alisha A. Alaimo
Corporate headquarters
Cambridge, Massachusetts

Forecasts